Spectrum Pharmaceuticals Submits Supplemental New Drug Application

Spectrum Pharmaceuticals SPPI today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration for a Ready-to-Use formulation of FUSILEV for Injection. This submission is in support of FUSILEV's use in colorectal cancer, which is currently under review by the FDA with a Prescription Drug User Fee Act action date of April 29 2011. FDA has up to 60 days to formally accept the submission.